Valerio Therapeutics Reports First Half 2024 Financial Results

Valerio Therapeutics has announced its financial results for the first half of 2024. The company recorded a net loss of €11 million, reducing the loss of €11.6 million for the same period in 2023. Non-recurring revenues amounted to €89,000, while operating expenses decreased by 6.8%. R&D expenses were also reduced by almost 23%.

The company recently acquired Emglev Therapeutics and created the subsidiary Valour Bio to focus on single domain antibodies. Valerio continues to expand its portfolio, including the current year of the VIO-01 clinical trial, currently in Phase 1.

The Company's cash position as of June 30, 2024 was €4 million, compared to €6.8 million as of December 31, 2023. This decrease is partly due to the acquisition of Emglev and loans received. The Company plans to continue its R&D efforts and explore potential commercial partnerships.